Clinical Trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

Completed Phase 1/2
View on ClinicalTrials.gov →
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the full human anti-tetanus toxin monoclonal antibody SNA02-48 injection and compare the Tetanus-antibody levels and safety of SNA02-48 with human tetanus immunoglobulin (HTIG) in Chinese adult participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-15; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Completed 2026-06-02
Trial Details
NCT Number NCT06939777
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions Tetanus
Enrollment 255 participants
Start Date 2025-04-28
Primary Completion 2025-12-08 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03